At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,959 enrolled
Drug / intervention
Placebo Vaginal Ring +1 morecombination
Likely dose
Dapivirine Vaginal Ring, 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women
International Partnership for Microbicides, Inc.·interventional·Posted Feb 27, 2012·Updated Oct 19, 2022
In Brief
A clinical study evaluating Placebo Vaginal Ring and Dapivirine Vaginal Ring, 25 mg for HIV Infections. Completed, enrolled 1,959 participants across 7 sites in 2 countries.
Detailed Summary
This is a double-blind, randomised, placebo-controlled study to assess the safety and efficacy of a silicone elastomer vaginal matrix ring.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesSouth Africa, Uganda
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartMar 2012
Primary CompletionDec 2016
TodayJul 2026
First PostedFeb 27, 2012
Enrollment StartMar 27, 2012
Primary CompletionDec 13, 2016
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 14.3 years ago
Interventions
Placebo Vaginal Ringcombination
Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
Dapivirine Vaginal Ring, 25 mgcombination
Dapivirine Vaginal Ring containing 25 mg of dapivirine